Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations

22Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The components of the Switch/Sucrose non-fermentable (SWI/SNF) complex are mutated in approximately 20% of human cancers. The A/T-rich interacting domain 1A (ARID1A) subunit has one of the highest mutation rates. Most notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas (OCCCs). We reported that inhibition of enhancer of zeste homology 2 (EZH2) is synthetically lethal in ARID1A-mutated OCCC.

Cite

CITATION STYLE

APA

Bitler, B. G., Aird, K. M., & Zhang, R. (2016). Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations. Molecular and Cellular Oncology, 3(1). https://doi.org/10.1080/23723556.2015.1032476

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free